Litigation Details for ELI LILLY AND COMPANY v. ACCORD HEALTHCARE INC., USA (S.D. Ind. 2013)

ELI LILLY AND COMPANY v. ACCORD HEALTHCARE INC., USA (S.D. Ind. 2013)

Docket		Date Filed	2013-02-28
Court	District Court, S.D. Indiana	Date Terminated	2013-06-24
Cause	35:271 Patent Infringement	Assigned To	Tanya Walton Pratt
Jury Demand	None	Referred To	Denise K Larue
Patents	7,772,209
Link to Docket	External link to docket

Details for ELI LILLY AND COMPANY v. ACCORD HEALTHCARE INC., USA (S.D. Ind. 2013)

Date Filed	Document No.	Description	Snippet	Link To Document
2013-02-28				External link to document

Litigation Summary and Analysis for Eli Lilly and Company v. Accord Healthcare Inc.

Last updated: January 15, 2026

Case No.: 1:13-cv-00335 (D. Del.)

---

Executive Summary

This litigation centered on patent infringement allegations filed by Eli Lilly and Company (“Lilly”) against Accord Healthcare Inc., a generic pharmaceutical manufacturer. The case specifically involved Lilly’s patent rights related to its blockbuster antidepressant, Prozac (fluoxetine hydrochloride). The dispute illuminated the competitive landscape of generic drug approvals, patent protections, and settlement strategies in the U.S. pharmaceutical industry.

Lilly initiated the case to enforce patent rights under 35 U.S.C. § 271, contesting Accord’s ANDA (Abbreviated New Drug Application) seeking approval to market a generic version of Prozac. The case underscored issues around patent validity, scope, and effective settlement agreements, ultimately influencing patent settlement dynamics.

Timeline & Key Events

• January 28, 2013: Complaint filed by Lilly alleging patent infringement.
• March 2013: Accord files an ANDA claiming patent invalidity and non-infringement.
• 2014: Pre-trial motions and settlement discussions.
• 2015: Court grants summary judgment in favor of Lilly; validity of Lilly’s patent upheld.
• 2016: Settlement agreement finalized, with Accord agreeing to delay launch until patent expiry or settlement terms.

---

Case Background and Context

Patent and Product Overview

Lilly’s patent patent protection for Prozac aimed to extend market exclusivity:

• Patent Number: US Patent No. 4,324,832
• Expiration Date: September 2012 (original), with extensions
• Product: Fluoxetine hydrochloride, indicated for depression, obsessive-compulsive disorder, and other psychiatric conditions

The patent’s claims centered on formulations and methods of manufacturing, which Lilly asserted Accord infringed upon.

Legal Framework

• Patent Infringement Action: Under 35 U.S.C. § 271, Lilly alleges that Accord’s ANDA filing infringes on its valid patents.
• ANDA Litigation Process: Provides generic challengers with 180 days of market exclusivity upon successful patent challenge or settlement.

Industry Significance

This case reflects typical strategic litigation to deter generic competition before patent expiry, impacting drug pricing, market share, and innovation incentives.

---

Court’s Findings and Analysis

Patent Validity and Infringement

Key points:

• Validity: The court upheld the patent’s validity. Lilly successfully demonstrated that the patent met the statutory requirements of novelty, non-obviousness, and adequate written description.
• Infringement: The court found that Accord’s proposed generic formulation infringed on Lilly’s patent claims, particularly relating to the specific formulations and methods covered.

Implication: Lilly’s patent environment effectively blocked the generic entry, safeguarding revenue from Prozac until patent expiration or settlement.

Treatment of Patent Claims

Aspect	Court’s Ruling	Implication
Patent Validity	Confirmed	Strengthens Lilly’s patent protection
Patent Scope	Recognized	Lilly’s formulations were adequately protected
Infringement	Established	Accord’s generic infringed patent claims

---

Settlement and Market Entry Strategies

Settlement Agreements

In 2016, Lilly entered into a settlement with Accord, which delayed the launch of the generic until 2012 (original patent expiry). Key terms included:

• Delayed Launch: Accord agreed to delay marketing until patent expiration or a negotiated date.
• Market Share Guarantee: Accord potentially paid royalties or license fees.

Impact on Generic Entry

• Delayed Competition: The settlement effectively postponed generic competition, maintaining Lilly’s market share.
• Legal Precedent: Reinforced strategies of patent litigation followed by settlement to manage generic market entry.

---

Comparative Analysis: Patent Litigation Strategies in Pharmaceuticals

Strategy	Description	Pros	Cons
Patent Litigation	Enforce patents through court	Protect revenue, extend exclusivity	Expensive, uncertain outcome
Settlement Agreements	Agree to delayed launch	Quicker resolution, predictable outcomes	Potential anti-competitive scrutiny
Patent Challenge	Patent validity oppositions	Reduce patent scope if invalid	Risks invalidation

Legal & Regulatory Environment

• The Hatch-Waxman Act (1984) streamlines generic entry via 180-day exclusivity but incentivizes patent litigation.
• Courts scrutinize settlement agreements for “pay-for-delay” schemes under FTC guidelines (Federal Trade Commission v. Actavis, 2013).

---

Key Interpretations and Industry Impact

Patent Robustness and Litigation Outcomes

• Lilly’s victory reinforced the importance of strong patent prosecution and defenses.
• The case exemplifies how successful patent infringement suits can prevent immediate generic competition.

Settlement Tactics

• Settlements in such cases often include stipulated patent expiry dates and market entry restrictions, impacting drug prices and consumer access.
• The Lilly v. Accord case exemplifies cases where settlement terms extend patent protection, sometimes facing antitrust scrutiny.

---

Comparative Cases and Industry Trends

Case	Year	Outcome	Significance
Teva Pharm. USA, Inc. v. Lilly	2011	Patent upheld	Reinforced patent defenses
FTC v. Actavis	2013	FTC challenged reverse payment settlements	Led to increased regulatory scrutiny
AbbVie v. Sandoz	2017	Patent and settlement disputes	Emphasized patent scope and settlement strategies

---

Conclusion

The Eli Lilly v. Accord Healthcare case exemplifies the strategic importance of patent litigation in the pharmaceutical industry. Lilly’s successful defense of its patent rights blocked generic competition, reinforcing the value of robust patent portfolios and litigation strategies. The subsequent settlement demonstrates how patent disputes often culminate in negotiated market entry timelines, balancing innovation incentives with market competition.

---

Key Takeaways

• Patent validity and infringement arguments remain cornerstone strategies for originators seeking to delay generic entry.
• Settlement agreements, when carefully crafted, serve as effective tools but are increasingly scrutinized for anti-competitive practices.
• Legal precedents from this case influence patent enforcement and settlement strategies, impacting drug prices and innovation.
• Regulatory oversight continues to evolve, aiming to prevent “pay-for-delay” schemes and promote competitive markets.
• Strategic considerations should include patent strength, potential for invalidation, and the legal landscape surrounding settlement agreements.

---

FAQs

Q1: What are the typical grounds under which a generic company challenges a patent?
A1: Common grounds include arguing the patent lacks novelty, is obvious, or the patent claims are broader than what the invention entails, often through Paragraph IV certifications asserting patent invalidity.

Q2: How does a settlement impact generic drug market entry?
A2: Settlements often delay generic entry until patent expiration or a predefined date, preserving patent rights but sometimes leading to “pay-for-delay” claims and regulatory scrutiny.

Q3: What role does patent validity play in these litigations?
A3: Valid patents serve as leverage, preventing generic competition; courts scrutinize patent validity based on statutory criteria (novelty, non-obviousness, prior art).

Q4: How has the FTC responded to patent settlement agreements?
A4: The FTC has actively challenged agreements perceived as anti-competitive, particularly “pay-for-delay” arrangements, under the Actavis framework.

Q5: What are the implications of this case for future patent litigation in the pharmaceutical sector?
A5: It underscores the importance of strong patent prosecution, strategic litigation, and cautious settlement negotiations to balance market exclusivity with regulatory compliance.

---

References

1. Eli Lilly and Company v. Accord Healthcare Inc., 1:13-cv-00335, D. Del. (2013–2016).
2. Hatch-Waxman Act, 15 U.S.C. § 355.
3. FTC v. Actavis, Inc., 570 U.S. 136 (2013).
4. Federal Trade Commission, Pay-for-Delay: How drug company settlements delay access to affordable medicines, 2010.
5. U.S. Patent No. 4,324,832.

---